News

Mount Sinai is celebrating one year since the establishment of the Mount Sinai-Clinique Healthy Skin Dermatology Center.

Bio-naïve patients and those without comorbidities had the highest treatment success rates with guselkumab.

Misinformation from outside sources creates unrealistic expectations for pregnancy and postpartum skin conditions like hyperpigmentation.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Gooderham continues a discussion on new data reinforcing the safety of topical delgocitinib, with minimal systemic absorption even under maximal use conditions.

2% and 4% formulations of the product were effective and tolerable for patients with varying scalp conditions.

Microbiome engineering offers strategies to modulate the skin microbiome, including non-targeted approaches like probiotics and targeted approaches like phage therapy.

Nearly all patients saw improvements in small, medium, and large depressions on the cheeks and temples with just a singular treatment session.

The significance of patient education and setting realistic expectations for the often-slow process of repigmentation in vitiligo treatment was a key focus of the discussion.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of April.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Compared to patients with rheumatoid arthritis and atopic dermatitis, those with vitiligo had a lower incidence of major adverse effects.

At the 2025 AAD Annual Meeting, Gooderham shared data on the negligible systemic exposure of delgocitinib cream for chronic hand eczema.

In the first Derm Dispatch episode, Renata Block, MMS, PA-C, and Peter Lio, MD, discuss integrative approaches to managing eczema, including the use of holistic treatments.

This month and all year round, we recognize the strides and contributions of female leaders in dermatology.

The integration of pharmacotherapy in obesity treatment provides a structured approach to weight loss for patients who struggle with traditional methods.

Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.

PASI and DLQI scores are closely linked, but stigma and residual effects may still impact patient QoL.

Explore the top headlines of the week including insights on clinical trials, CBD products, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about CBD products in dermatology, Journey Medical's launch of Emrosi for rosacea, the psychological impact of melanoma, and more.

This week, we feature top articles from our sister publications on clinical trials, FDA updates, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Learn more about the in-depth topics covered in the March 2025 print issue of Dermatology Times.

Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.

Explore the top headlines of the week including insights on recalls, expert pearls, and more.

Two-sample Mendelian randomization analysis explored lifestyle factors such as sleep, smoking, alcohol consumption, and sedentary behavior.

With an increasing demand for laser procedures, AI-based skin assessments may help ensure safer and more effective treatments.

The therapy, which combines clindamycin phosphate, adapalene, and benzoyl peroxide, was effective for Hispanic patients with moderate to severe lesions.

Dermatology Times is looking back on the top stories in dermatology from the month of March.